HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Correspondence: Submit a response Alert me when this article is cited Alert me when Correspondence are posted Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Diamond, S. G. Articles by Treciokas, L. J. Search for Related Content PubMed PubMed Citation Articles by Diamond, S. G. Articles by Treciokas, L. J.

Double-blind trial of pergolide for Parkinson's disease

Reed Neurological Research Center, UCLA School of Medicine, Los Angeles, CA.

Pergolide mesylate, a dopamine agonist, was studied as adjunctive therapy in ia 6-month double-blind trial in 20 patients with Parkinson's disease who were achieving less than optimal response from Sinemet. As pergolide or placebo was administered in increasing dosage, Sinemet was reduced if side effects developed. Both the pergolide and placebo groups improved significantly (p < 0.05). The pergolide group improved 30% at the end of 24 weeks, and the placebo group 23%. There was no significant difference between drug and placebo groups, possibly due to a fortuitous support group and the side effects that may have burdened the pergolide group. Nevertheless, pergolide had a definite antiparkinsonian effect.

Address correspondence and reprint requests to Dr. Markham, University of California, Los Angeles, Department of Neuroloky. Reed Neurological Research Center, UCLA School of Medicine, Center for the Health Sciences, Los Angeles, CA 90024.

Accepted for publication June 18, 1984.

This article has been cited by other articles:

				N. J. Diederich and C. G. Goetz The placebo treatments in neurosciences: New insights from clinical and neuroimaging studies Neurology, August 26, 2008; 71(9): 677 - 684. [Abstract] [Full Text] [PDF]

				C. G. Goetz, S. Leurgans, R. Raman, and G. T. Stebbins Objective changes in motor function during placebo treatment in PD Neurology, February 8, 2000; 54(3): 710 - 710. [Abstract] [Full Text] [PDF]

				C.H. Waters, M.L.J. Apuzzo, J.H. Neal, and L.P. Weiner Long-term Follow-up of Adrenal Medullary Transplantation for Parkinson's Disease J Geriatr Psychiatry Neurol, January 1, 1992; 5(1): 35 - 39. [Abstract] [PDF]